Tracking down contact activation - from coagulation in vitro to inflammation in vivo

International Journal of Laboratory Hematology

Volumn 36, Issue 3, 2014, Pages 374-381

  de Maat, S ^a   Tersteeg, C ^a   Herczenik, E ^a   Maas, C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bradykinin; Coagulation; Contact activation; Factor XII; Kallikrein

Indexed keywords

BRADYKININ; CHROMOGENIC SUBSTRATE; KALLIKREIN; KININ; BLOOD CLOTTING FACTOR;

ACUTE PHASE RESPONSE; ADVERSE OUTCOME; ANGIONEUROTIC EDEMA; BACTERIAL INFECTION; BIOASSAY; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CONTACT ACTIVATION; CONTACT SYSTEM; ENZYME ACTIVITY; ENZYME INHIBITOR COMPLEX; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNCTIONS OF THE HEMIC, LYMPHATIC AND RETICULOENDOTHELIAL SYSTEMS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFLAMMATION; INFLAMMATORY DISEASE; KALLIKREIN KININ SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PURIFICATION; REVIEW; WESTERN BLOTTING; BLOOD; ENZYME ACTIVATION; METABOLISM;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; ENZYME ACTIVATION; HUMANS; INFLAMMATION;

EID: 84898677514     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12222     Document Type: Review

References (48)

1. de Maat S, van Dooremalen S, de Groot PG, Maas C. A nanobody-based method for tracking factor XII activation in plasma. Thromb Haemost 2013;109:458-68.
2. Maas C, Govers-Riemslag JW, Bouma B, Schiks B, Hazenberg BP, Lokhorst HM, Hammarström P, ten Cate H, de Groot PG, Bouma BN, Gebbink MF. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008;118:3208-18.
3. Oschatz C, Maas C, Lecher B, Jansen T, Björkqvist J, Tradler T, Sedlmeier R, Burfeind P, Cichon S, Hammerschmidt S, Müller-Esterl W, Wuillemin WA, Nilsson G, Renné T. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011;34:258-68.
4. Golas A, Yeh C-HJ, Pitakjakpipop H, Siedlecki CA, Vogler EA. A comparison of blood factor XII autoactivation in buffer, protein cocktail, serum, and plasma solutions. Biomaterials 2013;34:607-20.
5. Ratnoff OD, Saito H. Amidolytic properties of single-chain activated Hageman factor. Proc Natl Acad Sci USA 1979;76:1461-3.
6. Griffin JH. Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc Natl Acad Sci USA 1978;75:1998-2002.
7. Hovinga JK, Schaller J, Stricker H, Wuillemin WA, Furlan M, Lämmle B. Coagulation factor XII Locarno: the functional defect is caused by the amino acid substitution Arg 353->Pro leading to loss of a kallikrein cleavage site. Blood 1994;84:1173-81.
8. Citarella F, Wuillemin WA, Lubbers YT, Hack CE. Initiation of contact system activation in plasma is dependent on factor XII autoactivation and not on enhanced susceptibility of factor XII for kallikrein cleavage. Br J Haematol 1997;99:197-205.
9. Thompson RE, Mandle R, Kaplan AP. Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain. Proc Natl Acad Sci USA 1979;76:4862-6.
10. Scott CF, Colman RW. Function and immunochemistry of prekallikrein-high molecular weight kininogen complex in plasma. J Clin Invest 1980;65:413-21.
11. Scott CF, Silver LD, Schapira M, Colman RW. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor. J Clin Invest 1984;73:954-62.
12. Wiggins RC. Kinin release from high molecular weight kininogen by the action of Hageman factor in the absence of kallikrein. J Biol Chem 1983;258:8963-70.
13. Pixley RA, Schmaier A, Colman RW. Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor. Arch Biochem Biophys 1987;256:490-8.
14. Asmis LM, Sulzer I, Furlan M, Lämmle B. Prekallikrein deficiency: the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII. Thromb Res 2002;105:463-70.
15. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991;266:7353-8.
16. Maas C, Meijers JC, Marquart JA, Bakhtiari K, Weeterings C, de Groot PG, Urbanus RT. Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma. Proc Natl Acad Sci USA 2010;107:9083-7.
17. Leeb-Lundberg LMF, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005;57:27-77.
18. Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost 2006;95:1003-10.
19. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009;8:998-1005.
20. Takeishi M, Mimori A, Nakajima K, Mimura T, Suzuki T. Reduction of factor XII in antiphospholipid antibody-positive patients with thrombotic events in the rheumatology clinic. Clin Rheumatol 2003;22:40-4.
21. Velayuthaprabhu S, Matsubayashi H, Sugi T, Nakamura M, Ohnishi Y, Ogura T, Tomiyama T, Archunan G. A unique preliminary study on placental apoptosis in mice with passive immunization of anti-phosphatidylethanolamine antibodies and anti-factor XII antibodies. Am J Reprod Immunol 2011;66:373-84.
22. Ratnoff OD. The relative amidolytic activity of Hageman factor (factor XII) and its fragments. The effect of high-molecular-weight kininogen and kaolin. J Lab Clin Med 1980;96:267-77.
23. Govers-Riemslag JW, Smid M, Cooper JA, Bauer KA, Rosenberg RD, Hack CE, Hamulyak K, Spronk HM, Miller GJ, ten Cate H. The plasma kallikrein-kinin system and risk of cardiovascular disease in men. J Thromb Haemost 2007;5:1896-903.
24. Esnouf MP, Burgess AI, Dodds AW, Sarphie AF, Miller GJ. A monoclonal antibody raised against human beta-factor XIIa which also recognizes alpha-factor XIIa but not factor XII or complexes of factor XIIa with C1 esterase inhibitor. Thromb Haemost 2000;83:874-81.
25. Dendorfer A, Wolfrum S, Wagemann M, Qadri F, Dominiak P. Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats. Am J Physiol Heart Circ Physiol 2001;280:H2182-8.
26. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003;3:311-7.
27. Renné T, Pozgajová M, Grüner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005;202:271-81.
28. Bird JE, Smith PL, Wang X, Schumacher WA, Barbera F, Revelli JP, Seiffert D. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait. Thromb Haemost 2012;107:1141-50.
29. Etscheid M, Breitner-Ruddock S, Gross S, Hunfeld A, Seitz R, Dodt J. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products. Vox Sang 2012;102:40-6.
30. Alving BM, Hojima Y, Pisano JJ, Mason BL, Buckingham RE Jr, Mozen MM, Finlayson JS. Hypotension associated with prekallikrein activator (Hageman-factor fragments) in plasma protein fraction. N Engl J Med 1978;299:66-70.
31. Van Rosevelt RF, Bakker JC, Sinclair DM, Damen J, van Mourik JA. Bradykinin-mediated hypotension after infusion of plasma-protein fraction. J Lab Clin Med 1982;100:288-95.
32. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358:2457-67.
33. Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C. In vivo roles of factor XII. Blood 2012;120:4296-303.
34. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, Renné C, Gailani D, Nieswandt B, Renné T. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006;203:513-8.
35. Matafonov A, Leung PY, Gailani AE, Grach SL, Puy C, Cheng Q, Sun MF, McCarty OJ, Tucker EI, Kataoka H, Renné T, Morrissey JH, Gruber A, Gailani D. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood 2014; Epub ahead of print.
36. Maas C, Renné T. Regulatory mechanisms of the plasma contact system. Thromb Res 2012;129(Suppl. 2):S73-6.
37. Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C. Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost 2007;5:1143-8.
38. Merlo C, Wuillemin WA, Redondo M, Furlan M, Sulzer I, Kremer-Hovinga J, Binder BR, Lämmle B. Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis 2002;161:261-7.
39. Doggen CJM, Rosendaal FR, Meijers JCM. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 2006;108:4045-51.
40. Konings J, Govers-Riemslag JWP, Spronk HMH, Waltenberger JL, ten Cate H. Activation of the contact system in patients with a first acute myocardial infarction. Thromb Res 2013;132:138-42.
41. Cushman M, O'Meara ES, Folsom AR, Heckbert SR. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood 2009;114:2878-83.
42. Borissoff JI, Heeneman S, Kilinç E, Kassák P, Van Oerle R, Winckers K, Govers-Riemslag JW, Hamulyák K, Hackeng TM, Daemen MJ, ten Cate H, Spronk HM. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 2010;122:821-30.
43. Pixley RA, De La Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A, Taylor FB Jr, Colman RW. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993;91:61-8.
44. Jansen PM, Pixley RA, Brouwer M, de Jong IW, Chang AC, Hack CE, Taylor FB Jr, Colman RW. Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 1996;87:2337-44.
45. Kouyoumdjian M, Nagaoka MR, Borges DR. Kallikrein-kinin system in hepatic experimental models. Peptides 2005;26:1301-7.
46. Hamberg U, Kärkkäinen T, Tallberg T. Kininogen by the SRI method in human serum during an acute phase inflammatory reaction. Adv Exp Med Biol 1986;198(Pt A):161-6.
47. Citarella F, Felici A, Brouwer M, Wagstaff J, Fantoni A, Hack CE. Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2). Blood 1997;90:1501-7.
48. Cichon S, Martin L, Hennies HC, Müller F, Van Driessche K, Karpushova A, Stevens W, Colombo R, Renné T, Drouet C, Bork K, Nöthen MM. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006;79:1098-104.